

ASX RELEASE

27 NOVEMBER 2024

SUCCESSFUL COMPLETION OF RETAIL ENTITLEMENT OFFER

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (**Amplia** or the **Company**), is pleased to announce the results of the fully underwritten retail component of its accelerated, non-renounceable entitlement offer (**Entitlement Offer**), which was announced to ASX on 30 October 2024.

Under the Entitlement Offer, eligible shareholders were entitled to subscribe for 1 fully paid ordinary share (**Share**) in Amplia for every 6.45 Shares held at an issue price of \$0.115 per Share, together with 3 options exercisable at \$0.1725 and expiring on 31 October 2027 (**Options**) for every 4 Shares subscribed for and issued under the Entitlement Offer.

The Options will be issued on or around 20 December 2024.

In conjunction with the Entitlement Offer, Amplia has raised approximately \$7.8 million under the institutional placement announced on 30 October 2024 and will raise a further \$0.3 million under its director placement (subject to Shareholder approval).

For further details of the capital raising, refer to the Company's Replacement Prospectus dated 1 November 2024 (available at www.asx.com.au).

Use of Proceeds

The proceeds of the capital raising will be used by Amplia to support completion of the ACCENT trial of the Company's lead compound, narmafotinib (the best-in-class Focal Adhesion Kinase (FAK) inhibitor) in pancreatic cancer, undertake a clinical trial in the US of narmafotinib in combination with FOLFIRINOX in pancreatic cancer (cleared IND from FDA for US-based trial) and general administrative and working capital.

Results of Retail Entitlement Offer

The Retail Entitlement Offer closed at 5.00pm (Melbourne time) on Friday, 22 November 2024.

The Retail Entitlement Offer was subscribed as follows:

Acceptance by Eligible Retail Shareholders	3,343,487 Shares
Acceptance by Eligible Retail Shareholders under the Top Up Facility	650,797 Shares
Total Shares applied for under the Retail Entitlement Offer	3,994,284 Shares
Retail Shortfall	22,889,055 Shares

The Retail Shortfall will be placed by Bell Potter Securities Limited and Taylor Collison Limited (**Underwriters**) to their sub-underwriters in accordance with the Underwriting Agreement between the Company and the Underwriters dated 1 November 2024 as described in the Replacement

Prospectus. The sub-underwriters of the Retail Entitlement Offer are professional and sophisticated investors who are clients of the Underwriters and are not related parties of the Company (**Retail Sub-Underwriters**).

The Shares to be issued under the Retail Entitlement Offer will rank equally with existing Shares (save for their entitlement to be issued attaching Options) and are expected to be issued on Friday, 29 November 2024.

In addition, the Company has offered 5,433,750 Options to the Retail Sub-Underwriters (subject to Shareholder approval).

Key Dates

Key remaining dates in relation to the capital raising are as follows:

Event	Date
Settlement of Retail Entitlement Offer	Thursday, 28 November 2024
Issue of Shares under the Retail Entitlement Offer	Friday, 29 November 2024
Commencement of trading of Shares issued under the Retail Entitlement Offer	Monday, 2 December 2024
EGM to approve the Director Placement and issue of Options to Placement participants and Retail Sub-Underwriters	Thursday, 19 December 2024
Allotment of Shares and Options under the Director Placement (subject to Shareholder approval) Allotment of Options to participants in the Entitlement Offer and Placement (subject to Shareholder approval in respect of Placement participants) Allotment of Options to Retail Sub-Underwriters (subject to Shareholder approval)	Friday, 20 December 2024
Expected commencement of trading of Options (subject to ASX granting quotation of the Options)	Monday, 23 December 2024

*Please note the dates set out above are indicative only and are subject to change. All dates and times are references to Melbourne, Australia time.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics Limited.

Investor Contact:

Dr Chris Burns

Chief Executive Officer

chris@ampliatx.com

Media Contact:

HACK Director, Haley Chartres

haley@hck.digital

+61 423 139 163

About Narmafotinib

Narmafotinib (AMP945) is the Company's best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic and other cancers, and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. The drug has successfully completed a healthy volunteer study, and is currently in an open-label Phase 2a trial in pancreatic cancer where a combination of narmafotinib and the chemotherapies gemcitabine and Abraxane® is being assessed for safety, tolerability and efficacy.

About the ACCENT Trial

The ACCENT trial is entitled '*A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients*'.

The ACCENT trial explores the use of narmafotinib in combination with standard-of-care chemotherapy of gemcitabine and Abraxane® in first-line patients with advanced pancreatic cancer. The trial is a single-arm open label study conducted in two stages. The first stage (Phase 1b), completed in November 2023, identified a 400 mg oral daily dose of narmafotinib, given in the days preceding regular chemotherapy infusion, as safe and well tolerated.

This second stage (Phase 2a), of the trial is designed to assess drug efficacy in combination with gemcitabine and Abraxane. The primary endpoints are Objective Response Rate (ORR) and Duration on Trial (DOT) with secondary endpoints being Progression Free Survival (PFS) and Overall Survival (OS). Safety and tolerability will continue to be assessed.

More information about the ACCENT trial, including a list of participating sites, can be found via the Amplia Therapeutics [website](#) and at ClinicalTrials.gov under the identifier [NCT05355298](#).

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [Twitter](#) (@ampliatx), [Threads](#) (@ampliatx) and [LinkedIn](#).